Oppenheimer Holdings Inc. reiterated their outperform rating on shares of Pieris Pharmaceuticals Inc. (NASDAQ:PIRS) in a report published on Wednesday morning. They currently have a $10.00 target price on the stock.
Separately, Roth Capital reiterated a buy rating and issued a $6.00 price objective on shares of Pieris Pharmaceuticals in a research report on Wednesday, September 28th.
Shares of Pieris Pharmaceuticals (NASDAQ:PIRS) opened at 1.8275 on Wednesday. The company’s market cap is $78.69 million. The firm has a 50 day moving average price of $1.64 and a 200-day moving average price of $1.79. Pieris Pharmaceuticals has a 52-week low of $1.26 and a 52-week high of $3.08.
Pieris Pharmaceuticals (NASDAQ:PIRS) last posted its quarterly earnings results on Wednesday, August 10th. The company reported ($0.14) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.15) by $0.01. Pieris Pharmaceuticals had a negative return on equity of 52.21% and a negative net margin of 346.01%. The firm earned $1.07 million during the quarter. Equities research analysts anticipate that Pieris Pharmaceuticals will post ($0.55) earnings per share for the current year.
Large investors have recently modified their holdings of the company. Lombard Odier Asset Management USA Corp increased its stake in shares of Pieris Pharmaceuticals by 20.3% in the second quarter. Lombard Odier Asset Management USA Corp now owns 3,166,915 shares of the company’s stock worth $5,099,000 after buying an additional 533,965 shares during the period. BVF Inc. IL purchased a new stake in Pieris Pharmaceuticals during the second quarter worth $389,000. Sabby Management LLC increased its stake in Pieris Pharmaceuticals by 823.4% in the second quarter. Sabby Management LLC now owns 1,615,992 shares of the company’s stock worth $2,602,000 after buying an additional 1,440,992 shares during the last quarter. Frontier Wealth Management LLC purchased a new stake in Pieris Pharmaceuticals during the second quarter worth $137,000. Finally, BlackRock Fund Advisors purchased a new stake in Pieris Pharmaceuticals during the second quarter worth $113,000. Institutional investors own 45.79% of the company’s stock.
Pieris Pharmaceuticals Company Profile
Pieris Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Its Anticalins proteins are a class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids.
Receive News & Ratings for Pieris Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.